Physician profile
Alan R Pollack
NPI 1790781979
$3,025.42
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $251 · 2021: $220 · 2022: $113 · 2023: $165 · 2024: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,419.28 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $203.89 | 2019-2024 | Airsupra |
| Abbvie INC. | $198.02 | 2019-2021 | |
| Novo Nordisk INC | $186.90 | 2019-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $173.54 | 2019-2021 | |
| Amgen INC. | $134.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $87.69 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Mylan Specialty L.P. | $63.74 | 2019-2020 | |
| Lilly USA, LLC | $49.46 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.08 | 2020-2023 | Xifaxan |
| Allergan, INC. | $44.61 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $40.17 | 2022-2024 | Dupixent |
| Abbott Laboratories | $37.98 | 2022 | |
| Sanofi Pasteur INC. | $37.64 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $33.13 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $29.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.37 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.31 | 2019 | |
| Bausch & Lomb Americas INC. | $22.93 | 2023 | Miebo |
| Lifescan, INC. | $22.89 | 2022 | |
| Radius Health, INC. | $22.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.14 | 2020 | |
| Phathom Pharmaceuticals, INC. | $20.21 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $18.69 | 2021 | |
| Gilead Sciences, INC. | $17.18 | 2021 | |
| Ethicon US, LLC | $16.68 | 2019 | |
| Corcept Therapeutics | $16.11 | 2020 | |
| Dynavax Technologies Corporation | $8.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.